Everand Logo

Welcome to Everand!

  • STAT

    STAT+: Pharmalittle: J&J drops out of bidding for Horizon; FDA takes a harder line on fast-track approvals

    J&J said it does not intend to make an offer for Horizon Therapeutics, days after the developer of autoimmune- and inflammatory-disease medicines revealed they were in talks.
    by Ed Silverman Dec 05, 2022 3 minutes
    Source: Alex Hogan/STAT

    Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online meetings and deadlines has predictably returned. But what can you do? The world, such as it is, continues to spin. So why not give it a nudge in a better direction with a hot cup of stimulation? Our choice today is peppermint mocha. As always, you are invited to join us. Meanwhile,

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT1 min read
    Genetic Variant Common Among West African Descendants Contributes To Large Cardiovascular Disease Burden
    A new study in JAMA identifies a genetic variant commonly found in people of West African descent that raises a type of cardiovascular disease risk.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Sanders’ Pharma Pressure Campaign, AstraZeneca’s New ADC Factory, And More
    Sen. Bernie Sanders is testing the limits of the powers of a Senate chairman with little hope of advancing his drug-pricing agenda legislatively.

    Related Books & Audiobooks